Basket Study at Providence Medical Group
Providence Medical Group is currently enrolling patients for the following
basket studies:
A Phase 1/2 Study of Galinpepimut-S in Combination with Pembrolizumab (MK-3475)
in Patients with Selected Advanced Cancers (SELLAS)
Treatment agent: Galinpepimut-S (WT1 immunotx) + pembroPI: Jarrod Holmes, MD
Study Coordinator: Tracy Foster // Tracy.Foster@stjoe.org // (707) 521-3836 ext. 1136
Resources and Links: clinicaltrials.gov NCT No: NCT03761914
A Phase 1/2 Study of Galinpepimut-S in Combination with Pembrolizumab (MK-3475)
in Patients with Selected Advanced Cancers (SELLAS)
Treatment agent: Galinpepimut-S (WT1 immunotx) + pembro
PI:
Jarrod Holmes, MD
Study Coordinator: Tracy Foster //
Tracy.Foster@stjoe.org // (707) 521-3836 ext. 1136
Resources and Links:
clinicaltrials.gov NCT No: NCT03761914
Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination
With Another Anti-cancer Therapy for Treatment of Recurrent (Non-small
Cell) Lung Cancer. (GCT1046-04)
Treatment: ABBV-927 with ABBV-368, budigalimab (ABBV-181), and/or chemotherapy
PI:
Ian Anderson, MD
Coordinator: Tracy Foster //
Tracy.Foster@stjoe.org // (707) 521-3836 ext. 1136
Resources and Links: https://clinicaltrials.gov/ct2/show/NCT05117242?term=NCT05117242&draw=2&rank=1
Sponsor: Genmab
Study of Magrolimab in Participants with Solid Tumors
Treatment: Mabrolimab + Docetaxel
PI:
Ian Anderson, MD
Coordinator: Charity Behrend //
charity.behrend@providence.org // (707) 521-3830 ext. 1181
Resources and Links:
https://clinicaltrials.gov/ct2/show/NCT04827576?term=Gilead+GS-US-548-5918&draw=2&rank=1
Sponsor: Gilead Sciences, Inc.